London, UK – 11 July 2025 – Adtec Healthcare Limited, a leading innovator in Cold Plasma medical technology, today announced it has secured $12 million in strategic investment from two new partners: AIPO Fund, as lead investor, and SG Biomedical. This significant funding milestone will propel the company’s global expansion, support the development of a next-generation Cold Plasma medical device, and enable its entry into the U.S. market.
The announcement marks a major leap forward for Adtec Healthcare, which spun out from its parent company Adtec Plasma Technology Co., Ltd. (Japan) in June 2023. With over two decades of experience and pioneering leadership in Cold Plasma science, the company launched the first Cold Plasma medical device to market, used in hospitals and clinics across Europe to support wound care and infection control.
Now, with this substantial new investment, Adtec Healthcare is poised to scale its innovations globally.
Investment Will Accelerate:
- Development of a new-generation Cold Plasma medical device, incorporating advanced design, performance, and regulatory capabilities.
- U.S. market entry, with the company actively pursuing FDA regulatory approval to bring its technology to American clinicians and patients.
- Expansion into new international markets, including partnerships and distribution in regions previously beyond reach.
- Increased R&D, clinical validation, and manufacturing capacity to support growing commercial demand.
“We’re entering a transformative period for Adtec Healthcare,” said Mary McGovern, CEO of Adtec Healthcare. “This investment from AIPO Fund and SG Biomedical not only provides the capital we need to expand globally, but also reflects shared confidence in our vision: to make Cold Plasma a globally recognised and adopted standard in infection control and wound care. We’re proud of what our team has built, and excited to move forward with strong, experienced partners by our side.”
“We’ve spent over 20 years refining this technology,” added Francois Herbst, CTO of Adtec Healthcare. “From our early scientific breakthroughs to launching the first CE-marked Cold Plasma device, our commitment has always been to translate deep science into real clinical impact. This funding enables us to enhance our technology further and bring it to entirely new geographies where the need for non-antibiotic, non-invasive treatments is greater than ever.”
“This investment is not just about scale, but about strategic acceleration,” said Jeiram Jeyaratnam, CBDO. “Over the years, we’ve built strong foundations through clinical collaborations, hospital partnerships, and regulatory engagements. With AIPO Fund and SG Biomedical now supporting us, we can rapidly expand our commercial footprint — launching in the U.S., opening up new territories, and aligning with healthcare partners globally to ensure our Cold Plasma solutions are available wherever they are needed.”
AIPO Fund and SG Biomedical bring deep sector knowledge and international networks, supporting Adtec Healthcare’s goals of transforming wound care, reducing reliance on antibiotics, and making Cold Plasma a mainstay in modern clinical practice.
Legal counsel on the transaction was provided by FieldFisher London.
About Adtec Healthcare Limited
Adtec Healthcare Limited is a UK-based medical technology company focused on pioneering Cold Plasma treatments for healthcare. The company was spun out from Adtec Plasma Technology Co., Ltd. (Japan) in June 2023, and has since become a leading voice in non-invasive, non-thermal plasma applications for infection control and chronic wound healing. Its Cold Plasma medical device was the first of its kind placed on the European market and is currently used across a variety of clinical settings.
Adtec Marketing Team
+44 208 737 5500